For millions of people using blockbuster weight-loss medications like Wegovy, Ozempic, Zepbound, or Mounjaro, the results are often transformative. However, a significant gap in efficacy exists: nearly one in four patients fails to see meaningful weight loss or health improvements.
While doctors have long attributed these differences to lifestyle or metabolism, new research suggests that our DNA might be the missing piece of the puzzle.
The Genetic Connection to Weight Loss
A study published in Nature, utilizing genetic data from nearly 28,000 individuals via 23andMe, has identified specific genetic markers that influence how effectively GLP-1 drugs work.
The researchers focused on the GLP1R gene, which is responsible for creating the receptors that these drugs target to trigger satiety (the feeling of fullness). The study found a specific variant, known as rs10305420, that appears to boost the medication’s effectiveness:
- One copy of the variant: Participants lost an average of 1.7 pounds more than those without it.
- Two copies of the variant: Participants lost an average of over 3 pounds more than those without it.
While a few pounds might seem modest, researchers note that in a population where the average weight loss is around 25 pounds, even small incremental gains are significant. At a public health level, even a 5% reduction in body weight can lead to major improvements in cholesterol and cardiovascular health.
How It Works: More Receptors, More Results
Why does this specific genetic quirk matter? Scientists hypothesize that this variant may improve the efficiency of transporting receptors to a cell’s surface.
“The genetic variant we found lands right in this gene [for] the GLP-1 receptor, which happens to be the target for these medications,” explains Adam Auton, vice president of human genetics at the 23andMe Research Institute.
Essentially, more receptors on the cell surface mean more “docking stations” for the drug to bind to, potentially making the signal to stop eating much stronger. Interestingly, this variant is also linked to a higher risk of gastrointestinal side effects. While unpleasant, increased nausea and appetite suppression can indirectly contribute to weight loss by reducing caloric intake.
The Complexity of Side Effects and Drug Types
The study also delved into why different drugs cause different reactions. For example, tirzepatide (Zepbound/Mounjaro) targets both GLP-1 and GIP receptors, whereas semaglutide (Wegovy/Ozempic) focuses on GLP-1.
Researchers identified a second variant (rs1800437 ) in the GIPR gene that specifically impacts how people react to tirzepatide.
– People with this variant experienced worse nausea and vomiting.
– The impact is compounded when combined with the first variant; individuals possessing both genetic markers were estimated to be 15 times more likely to experience vomiting when treated with tirzepatide.
The Path to Personalized Medicine
This research represents a “proof of concept” for the future of precision medicine. If clinicians can eventually use genetic testing to predict drug response, they could prescribe the most effective medication for a patient’s specific biology from day one, minimizing trial and error.
However, experts urge caution. Genetics is only one part of a complex equation. Several factors still dictate success, including:
– Demographics: Age and sex.
– Health Status: Existing conditions like diabetes.
– Lifestyle: Diet and physical activity.
– Diversity Gaps: Current findings are largely based on populations of European and Middle Eastern ancestry, meaning more research is needed to understand how these variants affect diverse global populations.
Conclusion
While genetics play a measurable role in how much weight a person loses on GLP-1 medications, they are not the sole factor. The future of obesity treatment lies in a holistic approach that combines genetic insights with a deep understanding of an individual’s overall health and lifestyle.
